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ABSTRACT 
 
Background: Angiotensin II (Ang II) has an important role on cerebral microcirculation; however, its direct roles 
in terms of ischemic brain edema need to be clarified. This study evaluated the role of central Ang II by using 
candesartan, as an AT1 receptor blocker, in the brain edema formation and blood-brain barrier (BBB) disruption 
caused by ischemia/reperfusion (I/R) injuries in rat. Methods: Rats were exposed to 60-min middle cerebral artery 
(MCA) occlusion. Vehicle and non-hypotensive doses of candesartan (0.1 mg/kg) were administered one hour 
before ischemia. Neurological dysfunction scoring was evaluated following 24 h of reperfusion. Animals were then 
decapitated under deep anesthesia for the assessments of cerebral infarct size, edema formation, and BBB 
permeability. Results: The outcomes of 24 h reperfusion after 60-min MCA occlusion were severe neurological 
disability, massive BBB disruption (Evans blue extravasation = 12.5 ± 1.94 µg/g tissue), 4.02% edema, and 
cerebral infarction (317 ± 21 mm3). Candesartan at a dose of 0.1 mg/kg, without changing arterial blood pressure, 
improved neurological dysfunction scoring together with significant reductions in BBB disruption (54.9%), edema 
(59.2%), and cerebral infarction (54.9%). Conclusions: Inactivation of central AT1 receptors, if not accompanied 
with arterial hypotension, protected cerebral micro-vasculatures from damaging effects of acute stroke.
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INTRODUCTION 
 
he critical role of renin–angiotensin system 
(RAS) in cardiovascular and fluid homeostasis 
is well established and some evidence exists 
about the role of angiotensin II (Ang II) in ischemic 
neuronal injury [1-3]. Ang II also involved in the 
pathophysiology of the stroke and large body of 
evidence, suggesting that ischemic stroke is associated 
with increased post-ischemic plasma renin secretion [2, 
3]. The inhibition of angiotensin converting enzyme 
and blocking AT1 receptors reduced the damaging 
effects of the acute ischemia/reperfusion (I/R) injuries 
in animal stroke models [4-6]. However, neurovascular 
protective effects of RAS inhibition by AT1 receptor 
blockade against cerebral ischemic edema were not 
fully studied yet.  
The blood–brain barrier (BBB) is the main defendant 
of the central nervous system that controls its 
microenvironment. Cerebral ischemia activates 
complex sequences of pathophysiological events, and 
by disruption of BBB integrity, it allows the entry of 
unwanted and potentially toxic molecules to harm the 
brain [7]. BBB disruption, which happens during the 
acute phase of ischemia, may exacerbate brain injury 
by the induction of edema during reperfusion. Ischemic 
brain edema occurring during stroke per se is life 
threatening due to augmentation of intracranial 
pressure and herniation [8], and its conjunction with 
cerebral infarction intensifies the primary 
complications of ischemia injuries [9]. Developed 
brain edema observed after 24 hours of ischemia is 
mainly due to vasogenic edema caused by disruption or 
increased BBB permeability [10, 11]. The protection of 
BBB integrity reduces neuronal injury following 
ischemia [12]. Although the involvement of RAS was 
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suggested in pathophysiology of ischemic events 
including stroke, there is limited data about the role of 
RAS in the alteration of BBB integrity and induction of 
vasogenic brain edema following focal cerebral 
ischemia [13]. Therefore, in the present study, the 
effects of AT1 receptor blockade on brain edema and 
BBB integrity following transient focal cerebral 
ischemia in rats were investigated. 
It has been reported that AT1 receptor inhibition by 
non-hypotensive dose of losartan reduced cerebral 
edema and markedly prolonged survival in 
spontaneously hypertensive rats [13]. Pathologic 
remodeling of cerebral vessels that occur during 
chronic hypertension are said to interfere with the 
outcomes of neuroprotective agents [14]. To exclude 
these possibilities, we used the model of transient focal 
cerebral ischemia in normotensive rats.  
 
 
MATERIAL AND METHODS 
 
Male Sprague Dawley rats (270-330 g) were 
obtained from Central Animal House Facility of Shiraz 
Medical Sciences University (Shiraz, Iran). All the 
study protocols were approved by the Institutional 
Animal Ethics Committee of Shiraz Medical Sciences 
University, which follows the NIH Guidelines for care 
and use of laboratory animals (NIH declaration No. 85-
23, revised in 1996). Rats had free access to water and 
standard rat chow ad libitum and were housed in a 
well-ventilated, temperature-controlled environment 
(22-24°C), humidity (40-60%), and light period (07.00-
19.00). 
 
Induction of ischemia and reperfusion. All animals 
were anesthetized with i.p. injection of 400 mg/kg 
chloral hydrate. Core temperature was recorded 
continuously by rectal probe and maintained with a 
heating pad at 37 ± 1ºC. After neck surgery, the right 
common carotid artery was exposed through a midline 
neck incision. Cerebral ischemia was induced using the 
modified method of intraluminal middle cerebral artery 
(MCA) occlusion as described previously [15]. The 
right MCA was occluded with a 3-0 surgical nylon 
filament. The filament was inserted from the external 
carotid artery into the internal carotid artery until 
reaching the origin of MCA. Reperfusion of the 
ischemic region started after 1 h of MCA occlusion by 
gently removing the filament. Finally, all incisions 
were sutured, and the animal was allowed to recuperate 
during 24 h of reperfusion period. In some animals, 
arterial blood samples were taken from tail artery for 
the measurements of arterial pH and blood gases at 10 
min before and 30 min after MCA occlusion as well as 
10 min after the start of reperfusion.  
 
Experimental protocol. Animals were randomly 
divided into three main groups with 32 rats per group. 
Group 1 (Sham): All rats underwent the surgery at the 
neck region and received a single intravenous injection 
of the vehicle (1 ml/kg 0.1 normal sodium carbonate 
solution) without being exposed to brain ischemia. 
Group 2 (control ischemic): rats underwent the surgery 
at the neck region, as in the sham group, and received 
the vehicle 1 h before exposure to 60 min MCA 
occlusion followed by 24 h reperfusion. Group 3 
(Candesartan-treated ischemic): all procedures 
performed here were similar to control ischemia with 
the exception of receiving a single intravenous 
injection of 0.1 mg/kg candesartan (Toronto Research 
Chemical Inc, Canada) at 1 h before induction of 
ischemia.   
Experiments were performed on four sets of animals 
(n = 8) within each group. The first set of animals was 
studied to determine neurological score and infarct 
size. The assessment of the brain edema formation was 
performed in the second set of animals. The third set of 
animals was used for the detection of BBB 
permeability. In the fourth set of animals, posterior tail 
artery was cannulated to continuously record the mean 
arterial blood pressure during the experiment and 
control of physiological parameters.  
 
Evaluation of neurological outcome. Behavioral 
tests were performed in rats 24 h after the termination 
of MCA occlusion. A five-point grading scale of 
neurological deficit scoring was used as described 
previously [5]. In brief, rats with normal motor 
function were assigned as grade 1. Rats that showed 
flexion of contralateral torso or forelimb upon lifting 
by their tail received grade 2. Grade 3 was for circling 
to the contralateral side of the occlusion. Grade 4 was 
assigned to the loss of righting reflex and decreased 
resistance to lateral push, and finally grade 5 was for 
no spontaneous motor activity.  
 
Cerebral infarct size. Cerebral infarct size was 
measured according to the method of Swanson et al. 
[16]. Accordingly, the brain was dissected into six 2 
mm-thick slices in the coronal plane and stained with a 
2% solution of 2,3,5-triphenyltetrazolium chloride 
(Molekula, UK) then was fixed in buffered formalin. 
Images of the stained sections were taken, and the 
infarction areas were quantified by image analyzer 
software (NIH Image Analyzer). Cerebral infarction 
volume was calculated as described previously [17]. 
 
Blood-brain barrier permeability. The rats chosen 
for the assessment of BBB integrity were deeply anes-
thetized, and a catheter was placed into their lateral tail 
vein. Slow infusion of 2% Evans blue solution (1 
ml/kg, Sigma Chemical Co., UK) was carried out for 5 
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min, in the sham group, 30 min after neck surgery and 
in the ischemic groups, 30 min after the termination of 
MCA occlusion. After neurological assessment, the 
rats were deeply anesthetized, and 250 ml warm nor-
mal saline (37ºC) was infused to the left ventricular 
catheter to wash out the remnants of Evans blue from 
general circulation. After decapitation, the brain was 
gently excised, the cerebellum and olfactory bulb were 
removed, and with the help of a brain matrix, the rest 
was divided into right and left hemispheres. Each hem-
isphere was carefully weighed and homogenized in 2.5 
ml phosphate buffered saline. Evans blue absorbance 
was measured in the extracted supernatant at 610 nm 
by a spectrophotometer (UV 7500, Spectro Lab, Eng-
land), and tissue Evans blue concentration (µg/g wet 
tissue) was calculated against a standard curve [18].  
 
Brain edema. The wet/dry weight method was used 
to measure the absolute brain water contents (ABWC). 
In brief, rats were killed under deep anesthesia, quickly 
decapitated, and the removed brain was placed in the 
brain matrix to separate the cerebellum and the 
olfactory bulb. Subsequently, through a midline 
sagittal incision the brain was divided into the right and 
the left hemispheres. Each hemisphere was placed in a 
separate pre-weighed container to measure its wet 
weight. Then, the container and the tissues were placed 
in a 110°C oven for 24 hours to obtain the tissues’ dry 
weight. ABWC of each hemisphere (%) and the 
percentage of edema formation (% ∆H2O) of the 
lesioned hemisphere were determined using equations 
2 and 3, respectively [5]. 
 
(2) ABWC (%) = [(wet weight – dry weight)/ wet 
weight] × 100 
 
(3) ∆H2O=%H2O lesioned hemisphere - %H2O of non-
lesioned hemisphere 
  
Statistical analysis. Most of Data are presented as 
mean ± SEM, and the significance of differences was 
evaluated using one-way analysis of variance 
(ANOVA) followed by Tukey’s test. Neurological 
deficit values are given as median values with quartile 
range (25 -75%). Significant differences were analyzed 
by Mann-Whitney U Test.  Statistical significance was 
accepted at P<0.05. 
 
RESULTS 
 
Mean arterial blood pressure. The results of blood 
pressure recordings indicated that mean arterial blood 
pressure of control ischemia and candesartan-treated 
rats were all in normal physiological range, and 
quantitatively no significant differences existed among 
them before, during, and after MCA occlusion (mean ± 
SEM, 92 ± 3 vs. 79 ± 2.9,  94 ± 1.6 vs. 83 ± 2.7, and 89 
± 3.5 vs. 77 ± 3.9, respectively, Fig. 1).  
 
Physiological parameters. All physiological 
parameters, such as PaO2, SaO2, PaCO2, pH, blood 
glucose, and body temperature, measured during the 
experiment were at normal physiological range. The 
comparison of Inter- and intra-group indicated no 
significant differences among the parameters proper 
values. 
 
Neurological outcome. Ischemia produced severe 
motor disabilities in control ischemia rats. However, 
there was a significant improvement in neurological 
dysfunction scoring of ischemic rats treated with 0.1 
mg/kg candesartan. The median (25-75% quartile 
range) of total deficit score for control ischemic group 
was 3 (3-3.5) compared with 1 (1.0-1.5) in 
candesartan-treated group (P = 0.002, Mann-Whitney 
U Test). 
 
Cerebral infarction. There were no traces of 
infarction in the left and right hemispheres of sham-
operated rats. MCA occlusion of the right hemispheres 
produced cerebral lesions in control ischemia rats. 
However, the pre-ischemic blockade of AT1 receptor 
with a non-hypotensive dose of candesartan (0.1 
mg/kg) significantly diminished cerebral lesion 
volumes by 54.9% (mean ± SEM, 143 ± 14 vs. 317 ± 
21 mm3, P<0.001, Fig. 2). 
 
Edema formation. The values of ABWC of the left 
and the right hemispheres of sham and left 
hemispheres of the ischemic rats were not statistically 
different  (Fig. 3).    Ischemia    elevated    brain   water  
 
 
 
 
Fig. 1. Mean arterial pressure (MAP) in  sham-operated rats, 
vehicle-treated control, and 0.1 mg/kg candesartan-treated is-
chemic rats at 10 minutes before middle cerebral artery occlu-
sion (MCAO), 30 minutes after MCAO, and 10 minutes after 
the beginning of reperfusion (n = 8). MCAO, Middle cerebral 
artery occlusion 
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Fig. 2. Cerebral infarct volume in vehicle-treated control and 
0.1 mg/kg candesartan-treated ischemic rats (n = 8). *P<0.001, 
compared with control group 
 
 
content of the lesioned hemispheres (right) of control 
ischemia rats to 83.3 ± 0.35%, while pre-ischemic 
blockade of AT1 receptors with candesartan (0.1 
mg/kg) could significantly diminish BWC (mean ± 
SEM, 80.3 ± 0.28%, P<0.001, Fig. 3).  The brain 
edema in ischemia control rats was significantly more 
than that in sham-operated rats. Pre-treatment with 
candesartan (0.1 mg/kg) significantly reduced the brain 
edema formation provoked by I/R injury by 59.2% 
(mean ± SEM, 1.64 ± 0.38% vs. 4.02 ± 0.32% 
P<0.001).     
 
Blood-brain barrier integrity disruption. Figure 4 is 
a sample photograph of the brain of the rats exposed to 
Evans blue extravasation technique. Evans blue extrav-
asation colors the brain tissue blue in the lesioned hem-
ispheres  of  ischemic  rats.  The  absence  of blue color  
 
 
in the right and the left hemispheres of sham (Fig. 4A) 
indicated that the induction of anesthesia, neck surgery, 
or manipulation of the carotid arteries per se did not 
affect BBB integrity. The appearances of bluish color 
in the lesioned hemispheres of ischemic rats indicated 
that the 60-min occlusion of the right MCA induced 
different magnitudes of BBB disruption (Fig. 4B and 
C). Qualitative comparisons of the blue color areas of 
ischemic hemispheres indicated that candesartan at 
dose of 0.1 mg/kg was able to attenuate BBB 
disruption (Fig. 4C). Figure 5 shows Evans blue 
concentrations of right side and left side of the brains 
of sham and ischemic rats receiving the vehicle  
or candesartan (0.1 mg/kg).  There  was  no statistically 
significant     difference    between    the     Evans    blue  
 
        
 
 
Fig. 3. Brain water content in left side and right side of brains 
in sham-operated rats, vehicle-treated control, and 0.1 mg/kg 
candesartan-treated ischemic rats (n = 8). †P<0.001 compared 
with sham group; *P<0.001 compared with control group. 
 
 
 
Fig. 4. Photograph of brains in sham-operated animal (A), and ischemic rats received vehicle (B) or 0.1 mg/kg candesartan (C). 
Animals received Evans blue 30 minutes after surgery or middle cerebral artery occlusion (MCAO). The presence of blue color 
depicted in B and C indicates that extravasation of Evans blue has occurred during ischemia/reperfusion injuries in the right side of 
the brain and its intensity is related to the quantity of damages of the cerebral vasculature of the lesioned side. 
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Fig. 5. Evans blue concentration in left side and right side of 
the brains in sham-operated rats, vehicle-treated control, and 0.1 
mg/kg candesartan-treated ischemic rats (n = 8). † P<0.001 
compared with sham group; * P<0.001 compared with control 
group.  
 
 
concentrations of left side brains of such groups. 
Moreover, there was no statistically significant 
difference between the Evans blue concentrations of 
left and right side of the brains of sham-operated rats. 
Evans blue concentration of ischemic hemisphere in 
control rats was significantly more than that in sham-
operated rats. Pre-treatment with candesartan (0.1 
mg/kg) significantly lowered Evans blue concentration 
and reduced BBB integrity disruption by 54.9% (mean 
± SEM, 5.63 ± 0.7 µg/g vs. 12.5 ± 1.94 µg/g, P<0.01). 
 
 
DISCUSSION 
 
The results of the present study demonstrated that in-
duction of focal cerebral ischemia significantly in-
creased ABWC of ischemic hemisphere. Pre-ischemic 
blocking of AT1 receptors by a non-hypotensive dose 
of candesartan significantly reduced ABWC in the  
ischemic hemisphere and lowered ischemic edema by 
59.2%. There are limited reports about the direct  
measurement of ischemic edema formation during AT1 
receptors inhibition in normotensive rats. Indirect  
evaluation of tissue swelling of the ischemic  
hemispheres using 2,3,5- triphenyltetrazolium chloride 
method [14, 19, 20] supports the results of the present 
study. 
The protective effects of AT1 receptor blockade on 
ischemic brain edema have been demonstrated in other 
experimental models and animal species. Blezer and 
colleagues [13] showed that the inhibition of AT1 
receptors by a non-hypotensive dose of losartan 
reduced cerebral edema and markedly prolonged 
survival in spontaneously hypertensive rats. Also, the 
inhibition of AT1 receptors by losartan prevented brain 
edema following global cerebral ischemia in the cat 
[21]. Moreover, the infusion of Ang II worsened 
cerebral edema following cerebral ischemia induced by 
bilateral occlusion of common carotid arteries in 
gerbils [22]. These results support the conclusions of 
the present study that Ang II and AT1 receptors might 
be involved in the formation of brain edema during I/R 
injuries. 
Mechanisms of the beneficial effects of AT1 receptor 
blockade on ischemic brain edema have not been fully 
elucidated. The present study as well as that of Blezer 
et al. [13] showed that the protective effects of AT1 
receptors blockade was achieved without hypotension. 
It seems that non-hypotensive mechanisms play a 
major role in these protective properties. Mechanisms 
such as the alteration of endothelial NO synthase 
activity and improved vasomotion of cerebral arterioles 
might also be involved in the protective effects of AT1 
receptor inhibition [23, 24]. Furthermore, recent 
evidence suggests that Ang II may be an important 
stimulus for the production of superoxide and 
peroxynitrite in blood vessels [25]. Oxygen-derived 
free radicals are known to increase the permeability of 
the BBB [26]. Furthermore, increased Ang II via AT1 
receptors may enhance cerebrovascular permeability 
and edema by the expression of matrix 
metalloproteinases [27]. Thus, the blocking of AT1 
receptors may reduce ischemic edema via protective 
effects on BBB integrity and lowering its permeability 
during ischemia. Hence, the next part of this study 
explored the role of Ang II and AT1 receptors in 
alteration of BBB integrity during I/R injuries. 
Mechanisms of the protective effects of AT1 receptor 
blockade on BBB integrity during ischemia are not 
fully elucidated. Several factors, such as oxygen free 
radicals [30], NO [31], and proteases [32], which are 
produced during ischemia, affect BBB permeability. 
The formation of free oxygen radicals in the brain 
tissues during or immediately after ischemia is known 
to increase BBB permeability [30]. Superoxide form-
ation in the blood vessels by Ang II stimulation of AT1 
receptors may also increase BBB permeability [26]. 
The blockade of AT1 receptors could, therefore, 
reverse the elevated BBB permeability seen during 
ischemia. This is possibly performed by increasing the 
activity of antioxidant enzymes, such as glutathione-s-
transferase and superoxide dismutase [29, 33] that 
reduce superoxide and peroxynitrite in blood vessels 
[34, 25]. Therefore, the protective effects of AT1 
receptor blockade on BBB integrity might be due to the 
decreased ROS production during cerebral ischemia. In 
conclusion, the results of this study demonstrated that 
the pre-ischemic blockade of AT1 receptors by 
candesartan reduced vasogenic brain edema formation 
by protecting the integrity of BBB following focal 
cerebral ischemia in the normotensive rats.  
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